Nextcure to give two presentations at society for immunotherapy of cancer annual meeting

Beltsville, md., oct. 05, 2022 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced two presentations at the society for immunotherapy of cancer (sitc) annual meeting, to be held in boston in november 8-12, 2022. nextcure will share new data from its phase 1 clinical study of nc762 and a high level overview of its ongoing nc410 combination study during poster sessions.
NXTC Ratings Summary
NXTC Quant Ranking